University of California San Francisco
Give to UCSFThere is a big, global problem: viruses such as HIV and COVID-19 mutate, but treatments for them don’t.
This will be one of the first and largest studies to examine the impact of factors like age and stress on vaccination effectiveness.
Further studies may reveal different patterns, including the possibility that evidence of abuse may not be apparent for months to follow, or failure by clinicians to identify abuse.
New results from an ongoing collaborative effort to slow the spread of COVID-19 shows that the prevalence of a coronavirus lineage, characterized by the L452R substitution and two other mutations in the virus’s spike protein, has significantly increased in recent months.
Susan Acton discovered ACE2 while searching for new cardiovascular drugs. Decades later, she was surprised to see it popping up in the news once COVID took hold.
A new study finds that inherited genetic variation plays a role in who is likely to benefit from checkpoint inhibitors, which release the immune system’s brakes so it can attack cancer.
A UCSF team has engineered a tiny antibody capable of neutralizing the coronavirus.
Patients with severe COVID-19 produce antibodies that paradoxically shut down their immune system’s virus-fighting response just when they need it most.
Few would have predicted last January that a pandemic would upend our daily lives. But one grueling year in, UCSF experts have a clearer view of the path ahead.
“It’s too soon to know if this variant will spread more rapidly than others," said Erica Pan, MD, MPH, State Epidemiologist for the California Department of Public Health.